Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel.
What you need to know
Who can take part?
Participants must have received and progressed (according to RECIST 1.1) on at least 1 line of therapy for the treatment of advanced/metastatic disease.
What is involved for me?
You will receive the study drug once every 3 weeks through intravenous (IV) infusion, which will take approximately one hour. You will be required to attend the clinic at least every week during treatment for a physical assessment, blood tests, ECGs and ongoing assessments. You will also receive ongoing tumour assessments via scans.
